FDA Approves Hyrimoz (adalimumab-adaz), a Biosimilar to Humira

FDA News, New FDA Approvals
October 31, 2018
A+ A-
Email Print

Article Link: FDA Approves Hyrimoz (adalimumab-adaz), a Biosimilar to Humira

Holzkirchen, Germany, October 31, 2018 – Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that the US Food and Drug Administration (FDA) approved its biosimilar, Hyrimoz (adalimumab-adaz). The FDA granted…

Source: FDA New Drug Approvals

Posted by

Newer Post
Older Post